---
document_datetime: 2023-09-21 18:27:07
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/revasc-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: revasc-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.0421846
conversion_datetime: 2025-12-28 14:22:35.114119
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 1 February 2004 please refer to module 8B.

•

- The MAH submitted to the EMEA on 10 May 2000 application for a Type I variation change in the  name  of  the  Marketing  Authorisation  Holder  from  Rhône-Poulenc  Rorer  S.A.  to  Aventis Pharma  S.A,  pursuant  to  Article  4  of  Commission  Regulation  (EC)  No  542/95  of  10  March 1995,  as  amended.  The  MAH,  with  the  submission  of  this  variation  updated  the  EU  local representatives in the PL.  The procedure started on 17 May 2000. A positive notification was signed  by  the  Head  of  Head  of  the  Biologicals  and  Biotechnology  sector  in  the  Unit  for  the

· The  MAH  submitted  to  the  EMEA  on  11  May  1998  an  application  for  the  transfer  of  the Marketing Authorisation from Novartis Europharm Limited UK to Rhône-Poulenc Rorer S.A. France,  pursuant  to  Article  3  of  Commission  Regulation  (EC)  No.  2141/96  of  7  November 1996. The procedure started 26 May 1998.  A positive opinion was signed by the Executive Director  at  the  EMEA  on  11  June  1998  and  forwarded  to  the  European  Commission,  which adopted a decision on 5 June 1998.  (EMEA/H/C/104/I/01) · The MAH submitted on 11 May 1998 an application for a Type I variation No 1 of Annex I, change in the content of the manufacturing authorisation, pursuant to Article 4 of Commission Regulation (EC) No 542/95 of 10 March 1995.  The procedure started on 26 May 1998.  The Head of Human Medicines Evaluation Unit at the EMEA signed a positive notification on 11 June 1998.  (EMEA/H/C/104/T/02) · The MAH submitted on 21 June 1999 a notification to the EMEA in order to introduce changes to  the  Package  Leaflet  not  connected  to  the  Summary  of  Product  Characteristics,  pursuant Article 10(3) of Council Directive No. 92/27/EEC of 31 March 1992. The procedure started on 1 December. The notification was signed by the Head of Human Medicines Evaluation Unit on 7 December 1998 and forwarded to the European Commission, which adopted a decision on 26 January 1999. (EMEA/H/C/104/N/03) · The MAH submitted to the EMEA on 26 November 1998 application for a Type I variation, extension of shelf-life of the finished product, pursuant to Article 4 of Commission Regulation (EC)  No  542/95  of  10  March  1995.  The  procedure  started  on 3  December  1998.  A  positive notification was signed by the Head of Human Unit at the EMEA on 17 December 1998 and forwarded  to  the  European  Commission,  which  adopted  a  decision  on  12  March  1999. (EMEA/H/C/104/I/04) · The  MAH  submitted  to  the  EMEA  on  on  9  July  1999  application  for  a  Type  I  variation,  a change of site for secondary packaging is sought through this application, pursuant to Article 4 of  Commission  Regulation  (EC)  No  542/95  of  10  March  1995,  as  amended.  The  procedure started on 14 July 1999. A positive notification was signed by the Head of Human Unit at the EMEA 28 July 1999 and forwarded to the European Commission, which adopted a decision on 29 July 1999.   (EMEA/H/C/104/I/05) · The MAH submitted to the EMEA on 16 December 1999 applications for a Type I variation, a change in analytical method for the biological assay of the active substance in bulk. This change is accompanied by a consequential change in specification of the bulk active, pursuant to Article 4 of Commission Regulation (EC) No 542/95 of 10 March 1995, as amended. The procedure started  on  21  January  2000.  A  positive  opinion  was  adopted  by  the  CPMP  15  March  2000. (EMEA/H/C/104/I/06) The same change has been submitted for the finished product (EMEA/H/C/104/I/07). The  MAH  submitted  to  the  EMEA  on  10  April  2000  application  for  a  Type  II  variation,  a change  in  the  specification  of  the  solvent,  water  for  injection,  pursuant  to  Article  6  of Commission Regulation (EC) No 542/95 of 10 March 1995, as amended. The procedure started on 14 April 2000. A positive opinion was adopted by the CPMP 26 July 2000 and forwarded to the European Commission, which adopted a decision on 2 August 2000. (EMEA/H/C/104/II/08) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Evaluation  of  Medicines  for  Human  Use  at  the  EMEA  16  June  2000  and  forwarded  to  the European Commission which adopted a decision on 1 August 2000.   (EMEA/H/C/104/I/09)

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                            | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amen ded on   |
|------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|------------------------------------------|
| Revision of sections 4.2, 4.4, 4.5, 4.8 of the SPC               | II/010               | II                       | 19.10.00                            | 22.01.01                                 |
| 5years renewal                                                   | R/011                | R                        | 25.05.02                            | 02.08.02                                 |
| Update of Summary of Product Characteristics and Package Leaflet | II/12                | II                       | 25.09.03                            | 27.01.04                                 |
| Change in test procedure of active substance                     | I/14                 | I                        | 26.06.03                            | 01.07.03                                 |
| Change in test procedures of the medicinal product               | I/15                 | I                        | 26.06.03                            | 01.07.03                                 |

1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II application. Medicinal product no longer authorised

N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.